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Background:  Renal  insufﬁciency  is  recognized  as  a predictor  of  mortality  and  adverse  outcome  in  heart
failure  (HF)  patients.  However,  the  long-term  clinical  outcome  of  cardiac  resynchronization  therapy  (CRT)
in Japanese  HF patients  with  renal  insufﬁciency  remains  uncertain.
Methods:  We  evaluated  67 consecutive  patients  who  underwent  CRT  at our  hospital.  The  patients  were
divided  into  two groups  according  to a  baseline  estimated  glomerular  ﬁltration  rate  (e-GFR)  cut-off  value
of 50  ml/min,  which  is  deﬁned  as  the  time  at which  patients  should  be  referred  to  a nephrologist,  by  the
Japanese  Society  of  Nephrology.  Follow-up  echocardiographic  ﬁndings  and  renal  function  were  examined
at 3–6  months  after  CRT.  Then,  we compared  long-term  clinical  outcomes  between  the  two  groups,  and
analyzed  the  effect  of CRT  on  renal  function,  echocardiographic  parameters  and  cardiac  survival.
Results:  During  a mean  follow-up  period  of  30.3  months,  patients  with  advanced  renal  insufﬁciency
(e-GFR  <  50  ml/min)  had  signiﬁcant  higher  all-cause  mortality  (log-rank  p = 0.033)  and  higher  cardiac
mortality  combined  with  HF  hospitalization  (log-rank  p  = 0.017)  than  patients  with  e-GFR  ≥ 50  ml/min.
Multivariate  analysis  revealed  that advanced  renal  insufﬁciency  was  an  independent  predictor  of  car-
diac mortality  combined  with  HF  hospitalization  (odds  ratio = 3.01,  p  = 0.008).  Subgroup  analysis  in  the
baseline  advanced  renal  insufﬁciency  group  revealed  that  patients  with  preserved  renal  function  by  CRT
(<10% reduction  in  e-GFR)  had  a higher  rate  of  decrease  of  left  ventricular  end-systolic  diameter  (−14.0%
vs. −0.8%,  p  =  0.023)  and  lower  cardiac  mortality  combined  with  HF hospitalization  (log-rank  p =  0.029)
compared  with  patients  with  deterioration  of  renal  function  (≥10%  reduction  in e-GFR).
Conclusions:  The  present  study  suggests  that advanced  renal  insufﬁciency  is quite  useful  for  the  prediction
of worsening  clinical  outcomes  in HF  patients  treated  by CRT.  Preservation  of  renal  function  by  CRT  brings
about  better  cardiac  survival  through  prevention  of  adverse  cardiac  events,  even  in HF patients  with
advanced  renal  insufﬁciency.
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Cardiac resynchronization therapy (CRT) improves left ventric-
lar function, symptoms, exercise capacity as well as endothelial
unction and reduces both morbidity and mortality in patients
ith advanced heart failure [1–4]. In the Comparison of Medical
herapy, Pacing, and Deﬁbrillation Heart Failure (COMPANION)
rial, all-cause mortality was reduced in patients on optimal
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medical therapy together with CRT, compared with optimal medi-
cal therapy alone [5].  About two-thirds of hospitalized heart failure
patients have renal insufﬁciency [6].  Heart failure and renal insuf-
ﬁciency actively interact pathophysiologically with each other,
and renal insufﬁciency is recognized as an independent predictor
of mortality and adverse outcome in heart failure patients [7,8].
Estimated glomerular ﬁltration rate (e-GFR) is used as the best
value for estimating renal function, and recently, the Japanese GFR
estimated equation for the evaluation of Japanese renal function
was deﬁned by the Japanese Society of Nephrology in 2008. The
relationship between renal insufﬁciency and clinical outcomes
in patients with CRT and the effect of CRT on renal function
have not been fully studied [9–13]. Especially, these evaluations
still have not been carried out in Japanese heart failure patients,
vier Ltd. All rights reserved.
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Table 1
Baseline clinical characteristics according to e-GFR.
e-GFR < 50 (n = 32) e-GFR ≥ 50 (n = 35) p-Value
Age (years) 69.8 ± 9.6 60.2 ± 17.8 0.009
Male 22 (68.8%) 25 (71.4%) 0.811
e-GFR (ml/min) 33.9 ± 13.0 66.1 ± 16.0 <0.001
NYHA 2.75 ± 0.67 2.80 ± 0.72 0.770
Ischemic HF 6 (18.8%) 6 (17.1%) 0.864
Hypertension 13 (40.6%) 7 (20.0%) 0.065
Diabetes mellitus 8 (25.0%) 11 (31.4%) 0.560
Atrial ﬁbrillation 14 (43.8%) 7 (20.0%) 0.036
Ventricular arrhythmia 8 (25.0%) 14 (40.0%) 0.192
QRS  duration (ms) 156.1 ± 36.7 143.6 ± 36.4 0.166
LBBB 16 (50.0%) 15 (42.9%) 0.558
RBBB 3 (9.4%) 4 (11.4%) 0.784
Serum BNP (pg/ml) 849.9 ± 744.2 517.2 ± 838.5 0.096
LVEDd (mm) 63.9 ± 9.5 66.9 ± 11.5 0.256
LVESd (mm)  54.4 ± 10.4 56.4 ± 12.5 0.491
EF  (%) 27.8 ± 10.1 30.8 ± 10.4 0.212
ACE-I or ARB 22 (68.8%) 27 (77.1%) 0.439
-Blocker 12 (37.5%) 25 (71.4%) 0.005
Spironolactone 13 (40.6%) 26 (74.3%) 0.193
Diuretic 28 (87.5%) 31 (88.6%) 0.893
Inotropic agent 4 (12.5%) 5 (14.3%) 0.830
CRT-D implantation 17 (53.1%) 27 (77.1%) 0.039
e-GFR, estimated glomerular ﬁltration rate; NYHA, New York Heart Association; HF,
heart failure; LBBB, left branch bundle block; RBBB, right branch bundle block; BNP,
B-type natriuretic peptide; LVEDd, left ventricular end-diastolic diameter; LVESd,
left  ventricular end-systolic diameter; EF, ejection fraction; ACE-I, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT-D, cardiac02 J. Hosoda et al. / Journal o
sing the Japanese GFR estimated equation as an index of renal
unction. We  sought to analyze the impact of renal insufﬁciency
n long-term clinical outcomes in heart failure patients treated
ith CRT. Furthermore, we determined the effect of CRT on renal
unction, especially focusing on heart failure patients with renal
nsufﬁciency by analyzing cardiac survival.
aterials and methods
tudy population
We evaluated heart failure patients who underwent CRT at
ur hospital between 2004 and 2008. The selection criteria for
RT included advanced symptomatic heart failure despite opti-
al  medical therapy, which was applied to the patients according
o the current guidelines and clinical standards. A CRT-P (pace-
aker) or CRT-D (deﬁbrillator) was implanted transvenously, and
 left ventricular (LV) pacing lead was inserted through the coro-
ary sinus and positioned as far as possible in the venous system,
referably in a posterolateral vein. Optimization of the devices,
uch as atrioventricular delay, was performed by echocardiogra-
hy. Patients who had no data on baseline e-GFR just before CRT
mplantation were excluded. Accordingly, a total of 67 patients with
aseline data undergoing transvenous pectoral implantation of a
RT-P or CRT-D were included in the present analysis. e-GFR was
alculated using the Japanese GFR estimated equation: e-GFR (in
l/min/1.73 m2) = 194 × (serum creatinine in mg/dl)−1.094 × (age in
ears)−0.287 × (0.739 if female). The patients were divided into two
roups by baseline e-GFR; no or mild renal insufﬁciency group (e-
FR ≥ 50 ml/min, n = 35) and advanced renal insufﬁciency group
e-GFR < 50 ml/min, n = 32). This e-GFR cut off value of 50 ml/min
as deﬁned as the time that patients with chronic kidney disease
CKD) should be referred to a nephrologist, according to the clinical
ractice guidelines on CKD of the Japanese Society of Nephrology.
chocardiographic evaluation was performed before CRT implan-
ation and at 3–6 months’ follow-up. LV dimensions and ejection
raction were assessed by M-mode echocardiography. The primary
ndpoint of this study was hospitalization due to heart failure
r all-cause death during long-term follow up after implantation.
his study was approved by the ethical committee of our hospital
approval number B080703013).
tatistical analysis
Comparisons of quantitative and categorical variables between
roups were made using Pearson chi-squared (2) test or Student’s
-test. All continuous data were expressed as mean ± standard devi-
tion (SD). Kaplan–Meier analysis was used to assess time-related
utcomes, and statistically signiﬁcant differences were tested using
he log-rank test. Separate univariate and multivariate Cox regres-
ion models with a forward stepwise approach were run to assess
he crude and multivariate adjusted odds ratios (ORs), which are
resented with 95% conﬁdence intervals (CIs). For all tests, a p-
alue < 0.05 was  considered statistically signiﬁcant. All statistical
nalyses were carried out using SPSS.
esults
aseline characteristics
The mean age of the study population was  64.8 ± 15.1
ears, and 70.1% were men. The etiology of heart failure was
schemic in 17.9%, dilated cardiomyopathic in 65.7%, and other
auses in 16.4%. These patients had advanced heart failure with
ean New York Heart Association of 2.78 ± 0.69, LV ejectionresynchronization therapy deﬁbrillator.
fraction (LVEF) of 29.4 ± 9.9%, and QRS duration of 149.6 ± 36.8 ms.
The proportion of patients receiving an angiotensin-converting
enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)
was 73.1%, and a -blocker was  55.0%. Mean baseline e-GFR
was 50.7 ± 21.8 ml/min. Baseline clinical characteristics, classiﬁed
according to e-GFR, are listed in Table 1. Compared to those in the
no or mild renal insufﬁciency group, patients in the advanced renal
insufﬁciency group were older (p = 0.009), had lower usage of -
blockers (p = 0.005), and had a higher prevalence of atrial ﬁbrillation
(p = 0.036) and CRT-D implantation (p = 0.039). Echocardiographic
left ventricular dimensions and LVEF did not differ between the two
groups.
Impact of baseline renal function on clinical outcomes
During a mean follow-up period of 30.3 ± 22.0 months, 25
(37.3%) of 67 patients died of any cause, including 12 (17.9%) cardiac
deaths, and 21 (31.3%) patients were hospitalized for heart failure.
In Kaplan–Meyer analysis, survival free from all-cause death
was signiﬁcantly lower in the advanced than in the no or mild renal
insufﬁciency group (62.5% vs. 82.9% at 2 years, log-rank p = 0.033)
(Fig. 1). Survival free from cardiac death combined with heart fail-
ure hospitalization was  also signiﬁcantly lower in the advanced
than in the no or mild renal insufﬁciency group (53.1% vs. 74.3% at
2 years, log-rank p = 0.017) (Fig. 2).
In univariate Cox regression analysis, advanced renal insuf-
ﬁciency (e-GFR < 50 ml/min) was  associated with a higher risk
of cardiac mortality combined with heart failure hospitalization
(OR = 2.46, 95% CI 1.14–5.29, p = 0.022). Other clinical variables,
including B-type natriuretic peptide (BNP) and LV end-systolic
diameter (LVESd), were associated with higher risk of cardiac mor-
tality combined with heart failure hospitalization (Table 2).Multivariate Cox regression analysis controlling for age, sex,
BNP, and LVESd revealed that advanced renal insufﬁciency
(e-GFR < 50 ml/min) was  an independent predictor of cardiac mor-
tality combined with heart failure hospitalization (OR = 3.01, 95% CI
J. Hosoda et al. / Journal of Cardiology 60 (2012) 301–305 303
Fig. 1. Kaplan–Meier curves of survival free from all-cause death of no or mild renal
insufﬁciency group [estimated glomerular ﬁltration rate (e-GFR) ≥ 50 ml/min] and
advanced renal insufﬁciency group (e-GFR < 50 ml/min).
Fig. 2. Kaplan–Meier curves of survival free from cardiac death combined with
heart failure hospitalization of no or mild renal insufﬁciency group [estimated
glomerular ﬁltration rate (e-GFR) ≥ 50 ml/min] and advanced renal insufﬁciency
group (e-GFR < 50 ml/min).
Table 2
Univariate predictors of cardiac death combined with heart failure hospitalization
by Cox proportional hazard models.
Variable Odds ratio 95% CI p-Value
e-GFR < 50 ml/min 2.455 1.139–5.291 0.022
LVESd (per 1 mm increase) 1.042 1.008–1.077 0.016
BNP (per 100 pg/ml increase) 1.030 1.000–1.061 0.049
Deﬁbrillator 0.615 0.290–1.302 0.204
NYHA (per 1 increase) 1.357 0.815–2.262 0.241
ACE-I or ARB 0.719 0.290–1.781 0.476
Male 1.351 0.574–3.183 0.491
Age (per 1 year increase) 1.009 0.982–1.037 0.515
Atrial ﬁbrillation 1.255 0.567–2.778 0.575
-Blocker 0.821 0.391–1.722 0.601
Diabetes mellitus 1.005 0.442–2.285 0.990
e-GFR, estimated glomerular ﬁltration rate; LVESd, left ventricular end-systolic
diameter; BNP, B-type natriuretic peptide; NYHA, New York Heart Association;
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Table 3
Multivariate predictors of cardiac death combined with heart failure hospitalization
by  Cox proportional hazard models.
Variable Odds ratio 95% CI p-Value
e-GFR < 50 ml/min 3.009 1.329–6.813 0.008
LVESd (per 1 mm increase) 1.049 1.014–1.085 0.005
BNP  (per 100 pg/ml increase) 1.028 0.991–1.067 0.136
e-GFR, estimated glomerular ﬁltration rate; LVESd, left ventricular end-systolic
diameter; BNP, B-type natriuretic peptide.
1.33–6.81, p = 0.008) (Table 3). Therefore, long-term adverse car-
diac events were signiﬁcantly associated with e-GFR, even after
adjustment for all other covariates.
Effects of CRT on renal function and clinical outcomes
Follow-up e-GFR was calculated from the last value of serum
creatinine determined 3–6 months after implantation. Patients
who had no follow-up e-GFR data or had died less than 3 months
after CRT implantation were excluded. Therefore, among patients
included in the present study, 51 (76.1%) had follow-up data
of e-GFR. There was no signiﬁcant difference in mean e-GFR
change from baseline to follow-up between the advanced renal
insufﬁciency group and the no or mild renal insufﬁciency group
(+0.02 ± 8.57 ml/min vs. −2.64 ± 17.02 ml/min, p = 0.48).
Preserved renal function was deﬁned as a <10% reduction in
e-GFR, and deteriorated renal function was deﬁned as a ≥10%
reduction in e-GFR at follow-up when compared to baseline. A
total of 51 patients were subdivided into four groups: no or mild
renal insufﬁciency with preserved renal function subgroup (sub-
group A; n = 16), no or mild renal insufﬁciency with deteriorated
renal function subgroup (subgroup B; n = 9), advanced renal insuf-
ﬁciency with preserved renal function subgroup (subgroup C;
n = 13), and advanced renal insufﬁciency with deteriorated renal
function subgroup (subgroup D; n = 13). There was no signiﬁcant
difference in mean baseline e-GFR between subgroup C and sub-
group D (35.2 ± 11.1 ml/min vs. 35.5 ± 11.5 ml/min, p = 0.95). The
echocardiographic parameters and BNP at baseline and follow-
up were compared between subgroup C and subgroup D,  and the
relationship between the change in renal function and the CRT
response was  examined (Table 4). There was no signiﬁcant differ-
ence in baseline characteristics between subgroup C and subgroup
D. In subgroup C, the mean LVESd decreased signiﬁcantly from
51.2 ± 10.5 mm to 43.8 ± 13.3 mm (p = 0.009), and the mean LVEF
increased signiﬁcantly from 27.2 ± 12.0% to 41.1 ± 15.1% (p = 0.007).
In subgroup D, there was no signiﬁcant difference in echocardio-
graphic parameters and BNP from baseline to follow-up. The mean
rate of decrease of LVESd from baseline to follow-up in subgroup
C was signiﬁcantly higher than that in subgroup D (−14.0 ± 13.4%
vs. −0.8 ± 11.1%, p = 0.023). The mean rate of increase of LVEF in
subgroup C was  also signiﬁcantly higher than that in subgroup
D (+72.1 ± 87.0% vs. +5.0 ± 54.4%, p = 0.032). These results showed
that subgroup C was equal to CRT responder, even in the advanced
renal insufﬁciency group. In Kaplan–Meyer analysis, survival free
from cardiac death combined with heart failure hospitalization
in subgroup C was signiﬁcantly higher than that in subgroup D
(log-rank p = 0.029). There was no difference in survival free from
cardiac death combined with heart failure hospitalization between
subgroup A, subgroup B, and subgroup C (Fig. 3). These results
suggested that preservation of renal function by CRT brought
about better cardiac survival through prevention of adverse car-
diac events, even in patients with advanced renal insufﬁciency
(e-GFR < 50 ml/min).
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Table  4
Baseline clinical characteristics and mean changes of echocardiographic parameters and BNP from baseline to follow-up between subgroup C and subgroup D.
Subgroup C (n = 13) Subgroup D (n = 13)
Baseline Follow-up p-Value Baseline Follow-up p-Value
Age (years) 67.7 ± 12.7 71.8 ± 6.7
Male 10 (76.9%) 11 (84.6%)
e-GFR (ml/min) 35.2 ± 11.1 35.5 ± 11.5
Hypertension 5 (38.4%) 6 (46.2%)
Diabetes mellitus 2 (15.4%) 5 (38.4%)
Atrial ﬁbrillation 4 (30.8%) 6 (46.2%)
LVEDd (mm)  59.3 ± 8.9 55.0 ± 11.5 0.065 66.1 ± 10.2 67.5 ± 7.8 0.656
LVESd (mm)  51.2 ± 10.5 43.8 ± 13.3* 0.009 55.6 ± 11.4 57.6 ± 10.0 0.747
EF  (%) 27.2 ± 12.0 41.1 ± 15.1* 0.007 27.8 ± 7.6 30.6 ± 12.5 0.329
Serum BNP (pg/ml) 787.0 ± 801.4 510.7 ± 430.6 0.095 633.9 ± 663.6 699.3 ± 679.2 0.811
e-GFR, estimated glomerular ﬁltration rate; LVEDd, left ventricular end-diastolic diameter; LVESd, left ventricular end-systolic diameter; EF, ejection fraction; BNP, B-type
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* p < 0.05 compared between group C and group D at follow-up.
iscussion
There are some previous reports about the clinical outcome of
RT in heart failure patients with the complication of renal insufﬁ-
iency. Fung et al. analyzed 85 patients treated by CRT, and reported
igniﬁcantly higher all-cause mortality in patients with deterio-
ation of renal function after 3 months of CRT [9].  Shalaby et al.
uggested high serum creatinine to be an independent predictor of
ortality in patients undergoing CRT [10]. Recently, Lin et al. eval-
ated a large sample of 482 patients treated by CRT at Mayo Clinic
nd reported that survival was higher in patients with normal or
ild renal dysfunction than in those with CKD (72% vs. 57% at 3
ears, p < 0.01) [11]. There is only one report on the relationship
etween the effect of CRT and renal function in the Japanese popu-
ation [12]. However, in that report, e-GFR was calculated using the
odiﬁcation of Diet in Renal Disease (MDRD) equation [14]. We
sed e-GFR calculated by the Japanese GFR estimated equation as a
arker of renal insufﬁciency. The mean baseline e-GFR of this study
opulation was 50.7 ± 21.8 ml/min, and 32 patients were included
n the advanced renal insufﬁciency group (e-GFR < 50 ml/min).
atients with advanced renal insufﬁciency had signiﬁcant higher
ig. 3. Kaplan–Meier curves of survival free from cardiac death combined with heart
ailure hospitalization based on baseline estimated glomerular ﬁltration rate and
hange in renal function by cardiac resynchronization therapy. Subgroup A: no or
ild renal insufﬁciency with preserved renal function subgroup; Subgroup B: no
r mild renal insufﬁciency with deteriorated renal function subgroup; Subgroup C:
dvanced renal insufﬁciency with preserved renal function subgroup; Subgroup D:
dvanced renal insufﬁciency with deteriorated renal function subgroup.all-cause mortality (log-rank p = 0.033) and higher cardiac mortal-
ity combined with heart failure hospitalization (log-rank p = 0.017)
than patients with e-GFR ≥ 50 ml/min. If using the MDRD equation
for calculation of e-GFR in this study, however, the mean baseline
e-GFR was increased to 68.7 ± 29.4 ml/min, and 15 patients would
be included in the advanced renal insufﬁciency group, which were
much fewer than those in the case using the Japanese equation.
Moreover, there was no signiﬁcant difference in all-cause mortal-
ity or cardiac mortality combined with heart failure hospitalization
between the two groups (log-rank p = 0.696, log-rank p = 0.841).
These results suggested that the MDRD equation overestimated
renal function in the Japanese population, and on the other hand,
the Japanese GFR estimated equation was a precise evaluation of
renal function and this equation could be more suitable to estimate
clinical outcomes in the Japanese CRT patients.
We  decided the cut off value of e-GFR for dividing the patients
into two  groups to be 50 ml/min. In the clinical practice guidelines
on CKD of the Japanese Society of Nephrology, e-GFR < 50 ml/min is
deﬁned as the time at which patients with CKD should be referred
to a nephrologist. According to the guidelines, the e-GFR cut off
value is quite important, because the rate of decline of renal func-
tion in the general population with e-GFR < 50 ml/min is more than
twice in comparison to that in those with e-GFR between 60 and
70 ml/min [15].
Bai et al. suggested that in heart failure patients treated with a
biventricular device, chronic renal failure, diabetes mellitus (DM),
and history of atrial ﬁbrillation (AF) appeared to be associated
with a higher risk of death [16]. The present study revealed
advanced renal insufﬁciency (e-GFR < 50 ml/min) to be an indepen-
dent predictor of cardiac mortality combined with heart failure
hospitalization. However, DM did not affect clinical outcomes. It
is well known that DM is responsible for a high cardiac mortality
in patients with ischemic heart disease [17]. One possible expla-
nation for the results is that the proportion of ischemic etiology
in our study was much smaller than that in Bai’s study (17.9% vs.
66.6%). As for AF, it was  not also associated with a higher risk of
the adverse cardiac events in our study. Twenty-one patients had a
history of AF, of which 4 patients had permanent AF and 17 patients
had paroxysmal AF. A recent study concerning prognostic impor-
tance of AF patients with CRT suggested that paroxysmal AF was  not
associated with increased mortality, although permanent AF was an
independent predictor of mortality [18]. The possible explanation
for our results concerning AF may  be due to the low proportion of
the permanent AF patients.Previous studies revealed that renal insufﬁciency is a strong
predictor of mortality in heart failure patients in general. A meta-
analysis of 16 studies with 80,098 heart failure patients showed
that adjusted overall mortality is more than double in patients with
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dvanced renal insufﬁciency compared to those without insufﬁ-
iency (HR 2.31 p < 0.001) [6].  Heart failure and renal insufﬁciency
ctively interact pathophysiologically with each other. A decrease
n LV systolic function and cardiac output has an adverse effect
n renal function due to decreased renal blood ﬂow. In turn, renal
nsufﬁciency causes volume expansion secondary to sodium reten-
ion, hypertension, and atherosclerosis, and leads to severe heart
ailure [19]. Through such mechanisms, renal function is gradually
mpaired in the natural course of severe heart failure.
In the present study, concerning the baseline advanced renal
nsufﬁciency group (e-GFR < 50 ml/min), cardiac mortality com-
ined with heart failure hospitalization was signiﬁcantly lower in
he preserved renal function subgroup (subgroup C described in
he results) than in the deteriorated renal function subgroup (sub-
roup D). This means that preservation of renal function by CRT
n patients with advanced renal insufﬁciency (e-GFR < 50 ml/min)
as shown to bring about good efﬁcacy to prevent adverse cardiac
vents and consequently improve the cardiac survival rate, whose
ean value and standard deviation was almost equivalent to that
n the no or mild renal insufﬁciency group. We  focused on the effect
f CRT in subgroup C, and found that the mean rate of decrease in
VESd from baseline to follow-up with CRT treatment in subgroup
 was signiﬁcantly higher than that in subgroup D (−14.0 ± 13.4%
s. −0.8 ± 11.1%, p = 0.023). The mean rate of increase in LVEF in
ubgroup C was also signiﬁcantly higher than that in subgroup
 (+72.1 ± 87.0% vs. +5.0 ± 54.4%, p = 0.032). This result directly
howed that CRT had good effect on the better cardiac survival rate
hrough improving heart function and preserving renal function
ven in the advanced renal insufﬁciency group (e-GFR < 50 ml/min).
onsequently, the advanced renal insufﬁciency with deteriorated
enal function subgroup had worst clinical outcomes. Compared to
hat in subgroup C, the prevalence of hypertension or DM tended
o be higher in subgroup D (Table 4). This observation suggested
hat renal parenchymal damage caused by hypertension or DM
ight be a major cause of deteriorated renal function in subgroup
.
Based on these results, we conclude that the mechanism was as
ollows: CRT reduces LV dyssynchrony and improves LV systolic
unction. Improvement in LV systolic function, which correlates
ith reversal of LV remodeling, provides an increase in renal blood
ow and leads to preservation of renal function, which is one of the
echanisms of the improved clinical outcome in renal insufﬁciency
atients treated by CRT.
However, in order to conﬁrm the above mechanism, we have
o consider the following study limitations. One possible limitation
s that this study was a non-randomized, retrospective analysis.
nother possible limitation is that the total sample size was small,
nd follow-up echocardiographic assessment was  available in only
3% of the study population. Further study with a larger sample size
s needed to conﬁrm the results of this study.
onclusionsAdvanced renal insufﬁciency, deﬁned as e-GFR < 50 ml/min, pre-
icts a poor clinical outcome in heart failure patients treated by CRT.
nce renal function is preserved, however, CRT brings about a good
linical outcome, even in heart failure patients with advanced renal
[ology 60 (2012) 301–305 305
insufﬁciency. CRT can become one of the most effective therapeutic
options for quite high-risk patients with both severe heart failure
and renal insufﬁciency.
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